Sieg A, Walker S, Czygan P, Gärtner U, Lanzinger-Rossnagel G, Stiehl A, Kommerell B
Z Gastroenterol. 1983 Nov;21(11):644-50.
In 14 patients with cirrhosis of the liver and portal-systemic shunts the effect of a branched-chain amino acid-enriched elemental diet on portal systemic encephalopathy, routine laboratory parameters and plasma amino acids was investigated. In addition to the standard therapy including protein restriction (40 g/day) the patients received 44 g of an amino acid-protein mixture containing 30% of branched-chain amino acids and placebo over 3 months in a crossover regimen. Plasma valine and leucine increased significantly, whereas all other amino acids, including the ratio (formula: see text), remained unchanged. The electroencephalogram, number connection test, clinical state and laboratory parameters were not influenced by therapy with branched-chain amino acids. Thus, orally administered branched-chain amino acids probably have no influence on hepatic encephalopathy but are an adequate source of nitrogen in patients with cirrhosis of the liver.
对14例肝硬化伴门体分流患者,研究了富含支链氨基酸的要素饮食对门体性脑病、常规实验室参数及血浆氨基酸的影响。除了包括蛋白质限制(40克/天)在内的标准治疗外,患者在3个月内采用交叉方案接受了44克含30%支链氨基酸的氨基酸 - 蛋白质混合物和安慰剂。血浆缬氨酸和亮氨酸显著增加,而所有其他氨基酸,包括该比例(公式:见正文),均保持不变。脑电图、数字连接测试、临床状态和实验室参数均未受支链氨基酸治疗的影响。因此,口服支链氨基酸可能对肝性脑病没有影响,但却是肝硬化患者充足的氮源。